Christopher Gibson is CEO at RECURSION PHARMACEUTICALS, INC. (RXRX). They have made 45 open-market trades across 2 companies since 2006, most recently 2026-06-05.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 45 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RXRX | 883,735 | $3.1M |
| IFF | 12,054 | $1.1M |
| PACB | 111,386 | $193K |
| Total | $4.3M |
Shares reported on the most recent Form 4, priced at the 2026-06-05 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RXRX | SELL · 10b5-1 | 2026-06-05 | 2026-06-05 | $3.62 | $145K | -8.5% | +16.0% | +0.9% |
| RXRX | SELL · 10b5-1 | 2026-05-22 | 2026-05-27 | $3.08 | $123K | +7.1% | +13.4% | +15.0% |
| RXRX | SELL · 10b5-1 | 2026-05-07 | 2026-05-08 | $3.37 | $135K | -9.4% | +1.7% | -2.6% |
| RXRX | SELL · 10b5-1 | 2026-04-22 | 2026-04-24 | $3.61 | $144K | -0.6% | -14.3% | -12.9% |
| RXRX | SELL · 10b5-1 | 2026-04-07 | 2026-04-08 | $3.10 | $124K | +10.8% | -0.2% | +15.6% |
| RXRX | SELL · 10b5-1 | 2026-03-23 | 2026-03-25 | $3.25 | $130K | +3.1% | +13.4% | +2.1% |
| RXRX | SELL | 2026-02-19 | 2026-02-19 | $3.46 | $138K | -2.7% | -11.3% | -18.8% |
| RXRX | SELL | 2026-02-04 | 2026-02-06 | $4.12 | $165K | -5.8% | -11.1% | -17.2% |
| RXRX | SELL | 2026-01-20 | 2026-01-22 | $4.47 | $179K | -16.4% | -30.4% | -23.9% |
| RXRX | SELL | 2026-01-05 | 2026-01-07 | $4.25 | $170K | -8.2% | -17.0% | -33.5% |
| RXRX | SELL · 10b5-1 | 2025-12-19 | 2025-12-19 | $4.50 | $180K | -3.7% | +0.9% | -22.7% |
| RXRX | SELL · 10b5-1 | 2025-12-04 | 2025-12-05 | $4.63 | $185K | -5.9% | -12.2% | -28.8% |
| RXRX | SELL · 10b5-1 | 2025-11-19 | 2025-11-19 | $4.16 | $166K | +4.1% | +2.7% | -16.6% |
| RXRX | SELL · 10b5-1 | 2025-11-04 | 2025-11-06 | $5.21 | $208K | -7.6% | +7.1% | -13.3% |
| RXRX | SELL · 10b5-1 | 2025-10-23 | 2025-10-24 | $5.70 | $570K | -19.3% | -29.6% | -19.3% |
| RXRX | SELL · 10b5-1 | 2025-10-10 | 2025-10-10 | $6.04 | $604K | +4.2% | -18.3% | -14.9% |
| RXRX | SELL · 10b5-1 | 2025-09-25 | 2025-09-26 | $4.76 | $476K | +27.5% | +31.9% | -11.0% |
| RXRX | SELL · 10b5-1 | 2025-09-10 | 2025-09-12 | $4.71 | $471K | -1.0% | +12.2% | -7.1% |
| RXRX | SELL · 10b5-1 | 2025-08-26 | 2025-08-28 | $4.84 | $484K | -6.1% | +1.6% | -8.8% |
| RXRX | SELL · 10b5-1 | 2025-08-11 | 2025-08-13 | $5.28 | $3.3M | -11.4% | -11.4% | -13.6% |
| RXRX | SELL · 10b5-1 | 2025-03-27 | 2025-03-28 | $6.04 | $1.7M | -15.4% | +6.3% | -1.7% |
| RXRX | SELL · 10b5-1 | 2025-03-05 | 2025-03-07 | $6.48 | $259K | +3.1% | -34.2% | -28.4% |
| RXRX | SELL · 10b5-1 | 2025-02-05 | 2025-02-07 | $7.97 | $478K | +34.6% | -20.3% | -42.9% |
| RXRX | SELL · 10b5-1 | 2025-01-08 | 2025-01-13 | $7.18 | $287K | +5.3% | +19.8% | -20.8% |
| RXRX | SELL · 10b5-1 | 2024-12-04 | 2024-12-06 | $7.14 | $286K | -29.5% | -9.8% | -29.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.